Vivos Therapeutics Receives “Hold” Rating from Analysts Amid Market Fluctuations

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has been assigned an average recommendation of “Hold” by five rating firms monitoring the company, according to MarketBeat.com. This consensus reflects a mix of sentiments, with one analyst recommending a sell, two advocating a hold rating, and two suggesting a buy.

The average twelve-month target price for Vivos Therapeutics shares is currently set at $4.92. Recent evaluations from various research analysts indicate notable activity surrounding the company. On December 1, 2023, Zacks Research upgraded Vivos Therapeutics from a “strong sell” to a “hold” rating. Meanwhile, Ascendiant Capital Markets revised its target price from $6.50 to $5.50 while maintaining a buy rating in a report released on December 3, 2023. Conversely, Weiss Ratings reiterated a “sell (e+)” rating on October 8, 2023. Additionally, HC Wainwright initiated coverage on November 17, 2023, assigning a buy rating with a price objective of $7.00.

Market Performance and Financial Details

Trading data indicates a challenging period for Vivos Therapeutics, with shares opening at $2.06 on the NASDAQ on Tuesday. Over the past year, the stock has reached a low of $1.92 and a high of $7.95. The company’s 50-day moving average stands at $2.21, while the 200-day moving average is at $3.43. Vivos Therapeutics currently boasts a market capitalization of $18.52 million and carries a price-to-earnings (P/E) ratio of -1.16, alongside a beta of 6.89. The firm reports a quick ratio and current ratio of 0.78, with a debt-to-equity ratio of 3.31.

On November 19, 2023, Vivos Therapeutics released its quarterly earnings data, reporting an earnings per share (EPS) of ($0.49). This figure surpassed analysts’ expectations, which estimated an EPS of ($0.53). Revenue for the quarter was $6.78 million, exceeding projections of $4.49 million. Despite these positive indicators, the company faces challenges with a negative return on equity of 351.28% and a negative net margin of 98.77%. Analysts project that Vivos Therapeutics will report an EPS of ($1.79) for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company dedicated to developing and commercializing oral appliance therapy for treating obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System combines clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate sleep-disordered breathing through non-surgical, non-invasive approaches. The Vivos System includes a range of custom oral devices, digital workflow tools, and a structured treatment protocol designed to enhance patient outcomes.

For further developments on Vivos Therapeutics and related companies, interested parties may consider subscribing to MarketBeat.com’s daily email newsletter for concise updates on news and analysts’ ratings.